CVRX vs MDT
CVRX: CVRx offers a proprietary neuromodulation therapy for heart failure patients that leverages the body's own nervous system to improve symptoms and functional status. MDT: Medtronic is a global healthcare technology leader dedicated to alleviating pain, restoring health, and extending life through innovative medical devices and digital solutions.
Side-by-side fundamentals
| Metric | CVRX | MDT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1.68 | $87.75 | |
| Market cap | $45M | $112.2B | |
| P/E as of 2026-10-08 | n/a | 23.54 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2026 | n/a | 2.41 | |
| Net margin | -94.1% | +13.2% | MDT higher |
| Gross margin FY2025, SEC XBRL | +85.3% | n/a | |
| Operating margin | -90.5% | +17.8% | MDT higher |
| ROE | -135.6% | +9.7% | MDT higher |
| ROA | -50.9% | +5.2% | MDT higher |
| Debt / equity as of 2026-09-03 | 2.01 | 0.57 | MDT lower |
| Revenue growth (YoY) as of 2026-09-03 | +11.7% | +8.4% | CVRX higher |
| Revenue CAGR (3y) SEC XBRL | +36.1% | +5.2% | CVRX higher |
| Dividend yield as of 2026-09-03 | n/a | +3.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 14 | MDT higher |
| Beta as of 2026-09-03 | 1.49 | 0.36 | |
| 1-year return as of 2026-10-08 close | -81.6% | -10.3% | MDT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.